Iloperidone (Fanapt) vs Quetiapine (Seroquel XR)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Schizophrenia

Shared mechanism: Dopamine D2 and serotonin 5-HT2A receptors (antagonist) · full Schizophrenia pipeline

Iloperidone (Fanapt)

Marketed by Vanda Pharmaceuticals

Approved in Schizophreniasmall molecule
Partial signal

NCT00254202 · Phase 3 · completed

This 4-week, randomized, double-blind Phase 3 trial (Study 2 in the FANAPT label, n=604) compared iloperidone 24 mg/day with placebo and with ziprasidone as an active control in acute schizophrenia. The primary endpoint was change in PANSS total score at day 28. The FDA label states that iloperidone 24 mg/day was superior to placebo on this endpoint, so the primary was met; efficacy appeared similar to ziprasidone. Sources: CT.gov posted results and the FANAPT label (openFDA).

Next expected readout: November 2027 · NCT06961968 (registry estimate)

Reported efficacy

Change From Baseline in Positive and Negative Symptom Scale Total (PANSS-T) Score (4 weeks): Change in PANSS total score at day 28: iloperidone 24 mg/day -12.0 (SE 1.03) vs placebo -7.1 (SE 1.48) vs ziprasidone -12.3 (SE 1.44) (CT.gov); iloperidone was superior to placebo on the primary (FANAPT label, Study 2). (met)

Result source: NCT00254202

Quetiapine (Seroquel XR)

Marketed by Cheplapharm Arzneimittel GmbH and partners

Approved in Schizophreniasmall molecule
Weak signal

NCT00640601 · Phase 3 · completed

This was a nonrandomized, single-group, open-label study of 295 treated participants, without a placebo or active comparator. Although 56.88% were reported to have improved clinical benefit on the primary CGI-CB measure, the uncontrolled design cannot determine how much of the improvement was due to quetiapine rather than other factors.

Next expected readout: February 2032 · NCT07152184 (registry estimate)

Reported efficacy

Percentage of Subjects With Improved Clinical Benefit From Assessment of Clinical Global Impression-Clinical Benefit (CGI-CB) Scale From Baseline to Week 24 or End of Study (Baseline to 24 weeks (or end of study)): Percentage of Subjects With Improved Clinical Benefit From Assessment of Clinical Global Impression-Clinical Benefit (CGI-CB) Scale From Baseline to Week 24 or End of Study (Baseline to 24 weeks (or end of study)): Seroquel XR 56.88% (95% CI 50.8 to 62.8) (not_applicable)

Result source: NCT00640601

Results for Schizophrenia

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointIloperidone (Fanapt)Quetiapine (Seroquel XR)
PANSS total, change-12 vs -7.1−4.9 vs placebowk 4 · n 283NCT00254202
1 other result
  • 1.1 vs 12.4 wk 26 · n 150 · Phase 3 · secondary NCT01291511
-24 vs -15.9−8.1 vs placebowk 6 · n 150NCT01810380
1 other result
  • 102.3 vs 100.5 wk 12 · n 107 · Phase 3 · secondary NCT00640562
CGI-S, change—Trial running · NCT06961968-1.4 vs -0.9−0.5 vs placebowk 6 · n 150NCT01810380
1 other result
  • -1.5 vs -1.0 wk 12 · n 107 · Phase 3 · secondary NCT00640562
PANSS response—Trial running · NCT0696196862.7% vs 32.1%+30.6 vs placebowk 6 · n 150NCT01810380
PSP, change—Trial running · NCT0696196815.3 vs 9.4+5.9 vs placebowk 6 · n 138NCT01810380
Relapse (% of patients)—Trial running · NCT06961968—Not posted · NCT00159770

PANSS total, change

Iloperidone (Fanapt)
-12 vs -7.1−4.9 vs placebowk 4 · n 283NCT00254202
1 other result
  • 1.1 vs 12.4 wk 26 · n 150 · Phase 3 · secondary NCT01291511
Quetiapine (Seroquel XR)
-24 vs -15.9−8.1 vs placebowk 6 · n 150NCT01810380
1 other result
  • 102.3 vs 100.5 wk 12 · n 107 · Phase 3 · secondary NCT00640562

CGI-S, change

Iloperidone (Fanapt)
—Trial running · NCT06961968
Quetiapine (Seroquel XR)
-1.4 vs -0.9−0.5 vs placebowk 6 · n 150NCT01810380
1 other result
  • -1.5 vs -1.0 wk 12 · n 107 · Phase 3 · secondary NCT00640562

PANSS response

Iloperidone (Fanapt)
—Trial running · NCT06961968
Quetiapine (Seroquel XR)
62.7% vs 32.1%+30.6 vs placebowk 6 · n 150NCT01810380

PSP, change

Iloperidone (Fanapt)
—Trial running · NCT06961968
Quetiapine (Seroquel XR)
15.3 vs 9.4+5.9 vs placebowk 6 · n 138NCT01810380

Relapse (% of patients)

Iloperidone (Fanapt)
—Trial running · NCT06961968
Quetiapine (Seroquel XR)
—Not posted · NCT00159770
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Iloperidone (Fanapt): 4 of 4 rows · Quetiapine (Seroquel XR): 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricIloperidone (Fanapt)Quetiapine (Seroquel XR)
Dropout rate
34.6%a
NCT00254202 · Phase 3 · monotherapy · Schizophrenia · phase 3
show 24 more results
51.3%Iloperidone
NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3
—Iloperidone (Cross-titration and S
NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3
—Iloperidone (Relapse-prevention Ph
NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3
30.3%Iloperidone Gradual Switch
NCT01207414 · Phase 4 · registry result, not featured evidence
31.5%Iloperidone Immediate Switch
NCT01207414 · Phase 4 · registry result, not featured evidence
18.8%625 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—625 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—625 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
12.5%500 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—500 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—500 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
13.3%250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
6.7%250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
6.7%250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—125 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—125 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—50 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—50 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
38%b
NCT00640601 · Phase 3
show 7 more results
16.5%
NCT00640562 · Phase 3
—Seroquel IR
NCT01213836 · Phase 4 · registry result, not featured evidence
—Seroquel XR
NCT01213836 · Phase 4 · registry result, not featured evidence
20%
NCT00954122 · Phase 4 · registry result, not featured evidence
30.2%
NCT00779506 · Phase 4 · registry result, not featured evidence
—Quetiapine
NCT01810380 · Phase 3 · registry result, not featured evidence
20.8%Quetiapine Extended Release
NCT01810380 · Phase 3 · registry result, not featured evidence
Discontinued due to AEs
—a
NCT00254202 · Phase 3 · monotherapy · Schizophrenia · phase 3
show 24 more results
14.5%Iloperidone
NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3
—Iloperidone (Cross-titration and S
NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3
—Iloperidone (Relapse-prevention Ph
NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3
10.4%Iloperidone Gradual Switch
NCT01207414 · Phase 4 · registry result, not featured evidence
15%Iloperidone Immediate Switch
NCT01207414 · Phase 4 · registry result, not featured evidence
—625 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—625 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—625 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—500 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—500 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—500 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—125 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—125 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—50 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—50 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
14.6%b
NCT00640601 · Phase 3
show 7 more results
7.3%
NCT00640562 · Phase 3
—Seroquel IR
NCT01213836 · Phase 4 · registry result, not featured evidence
—Seroquel XR
NCT01213836 · Phase 4 · registry result, not featured evidence
2.9%
NCT00954122 · Phase 4 · registry result, not featured evidence
4.2%
NCT00779506 · Phase 4 · registry result, not featured evidence
—Quetiapine
NCT01810380 · Phase 3 · registry result, not featured evidence
2.6%Quetiapine Extended Release
NCT01810380 · Phase 3 · registry result, not featured evidence
Serious AEs
0.7%a
NCT00254202 · Phase 3 · monotherapy · Schizophrenia · phase 3
show 24 more results
—Iloperidone
NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3
3.3%Iloperidone (Cross-titration and S
NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3
4%Iloperidone (Relapse-prevention Ph
NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3
3.3%Iloperidone Gradual Switch
NCT01207414 · Phase 4 · registry result, not featured evidence
2.7%Iloperidone Immediate Switch
NCT01207414 · Phase 4 · registry result, not featured evidence
—625 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
0%625 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
0%625 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—500 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
0%500 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
0%500 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
14.3%250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
0%250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
7.1%250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
0%250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
0%250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
0%250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
0%125 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
0%125 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
0%50 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
0%50 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
11.2%b
NCT00640601 · Phase 3
show 7 more results
3.7%
NCT00640562 · Phase 3
0%Seroquel IR
NCT01213836 · Phase 4 · registry result, not featured evidence
0%Seroquel XR
NCT01213836 · Phase 4 · registry result, not featured evidence
2.9%
NCT00954122 · Phase 4 · registry result, not featured evidence
0%
NCT00779506 · Phase 4 · registry result, not featured evidence
1.3%Quetiapine
NCT01810380 · Phase 3 · registry result, not featured evidence
—Quetiapine Extended Release
NCT01810380 · Phase 3 · registry result, not featured evidence
Most frequent reported AEs
a
headache 20.3% (placebo 19.7%)
dizziness 17% (placebo 7.5%)
sedation 12.7% (placebo 8.2%)
NCT00254202 · Phase 3 · monotherapy · Schizophrenia · phase 3
show 18 more results
dizziness 11.6% (placebo 2.7%)
somnolence 8.3% (placebo 0%)
dry mouth 6.8% (placebo 0%)
NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3
dizziness 2.6% (placebo 2.7%)
headache 2% (placebo 3.3%)
insomnia 2% (placebo 4.7%)
NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3
dry mouth 17.9%
dizziness 17.5%
somnolence 14.2%
NCT01207414 · Phase 4 · registry result, not featured evidence
dizziness 22.3%
dry mouth 20.8%
insomnia 9.6%
NCT01207414 · Phase 4 · registry result, not featured evidence
625 mg
injection site pain 66.7%
injection site induration 60%
injection site swelling 20%
NCT01348100 · Phase 1/2 · registry result, not featured evidence
625 mg
headache 20%
nasal congestion 20%
anxiety 13.3%
NCT01348100 · Phase 1/2 · registry result, not featured evidence
500 mg
injection site pain 60%
injection site induration 26.7%
injection site swelling 20%
NCT01348100 · Phase 1/2 · registry result, not featured evidence
500 mg
nasal congestion 33.3%
constipation 13.3%
somnolence 13.3%
NCT01348100 · Phase 1/2 · registry result, not featured evidence
250 mg
back pain 7.1%
constipation 7.1%
headache 7.1%
NCT01348100 · Phase 1/2 · registry result, not featured evidence
250 mg
insomnia 20%
headache 13.3%
somnolence 13.3%
NCT01348100 · Phase 1/2 · registry result, not featured evidence
250 mg
constipation 14.3%
headache 14.3%
anxiety 7.1%
NCT01348100 · Phase 1/2 · registry result, not featured evidence
250 mg
headache 33.3%
insomnia 33.3%
dyspepsia 13.3%
NCT01348100 · Phase 1/2 · registry result, not featured evidence
250 mg
injection site pain 53.3%
headache 26.7%
nasal congestion 26.7%
NCT01348100 · Phase 1/2 · registry result, not featured evidence
250 mg
nasal congestion 40%
headache 26.7%
oropharyngeal pain 13.3%
NCT01348100 · Phase 1/2 · registry result, not featured evidence
125 mg
pruritus 50%
throat irritation 50%
upper respiratory tract infection 50%
NCT01348100 · Phase 1/2 · registry result, not featured evidence
125 mg
constipation 50%
agitation 0%
akathisia 0%
NCT01348100 · Phase 1/2 · registry result, not featured evidence
50 mg
blood creatine phosphokinase increased 50%
agitation 0%
akathisia 0%
NCT01348100 · Phase 1/2 · registry result, not featured evidence
50 mg
dizziness 50%
headache 50%
agitation 0%
NCT01348100 · Phase 1/2 · registry result, not featured evidence
b
somnolence 18%
dizziness 14.6%
sedation 14.2%
NCT00640601 · Phase 3
show 5 more results
somnolence 5.5%
dry months 4.6%
hypotension 4.6%
NCT00640562 · Phase 3
somnolence 3.2%
delusion 1.6%
dizziness 1.6%
NCT01213836 · Phase 4 · registry result, not featured evidence
psychotic disorder 1.6%
sedation 1.6%
sleep disorder 1.6%
NCT01213836 · Phase 4 · registry result, not featured evidence
constipation 25.5%
insomnia 23.4%
sedation 12.8%
NCT00779506 · Phase 4 · registry result, not featured evidence
somnolence 22.2% (placebo 5%)
weight increased 13.1% (placebo 3.7%)
dizziness 11.8% (placebo 0.6%)
NCT01810380 · Phase 3 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for 21 of these studies.
  2. bPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Iloperidone (Fanapt)

Time to Relapse NA vs 3.25 placebo months @ 26wk
time to event · months
NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3
CGI-S 3 vs 3.6 placebo score @ 26wk
absolute value · score
NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3
SDS -0.2 vs 1.8 placebo score @ 26wk
absolute change · score
NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3
CGI-C 2.826 score @ 12wk
absolute value · score
No placebo or comparator arm
NCT01207414 · Phase 4 · registry result, not featured evidence
show 1 more result
2.824 score @ 12wk
NCT01207414 · Phase 4 · registry result, not featured evidence
CGI-S -0.8 score @ 12wk
absolute change · score
No placebo or comparator arm
Change from baseline 3 cohorts combined
NCT01207414 · Phase 4 · registry result, not featured evidence
show 3 more results
-0.8 score @ 12wk
Change from baseline 3 cohorts combined
NCT01207414 · Phase 4 · registry result, not featured evidence
-0.9 score @ 12wk
Change from baseline 3 cohorts combined
NCT01207414 · Phase 4 · registry result, not featured evidence
-0.9 score @ 12wk
Change from baseline 3 cohorts combined
NCT01207414 · Phase 4 · registry result, not featured evidence

Quetiapine (Seroquel XR)

Clinical Benefit 56.88% (n=295) @ 24wk
responder rate · % of participants
No placebo or comparator arm
NCT00640601 · Phase 3
CGI-CB 1.41 score @ 24wk
absolute change · score
No placebo or comparator arm
NCT00640601 · Phase 3
PANSS Total 10.95 score @ 24wk
absolute change · score
No placebo or comparator arm
NCT00640601 · Phase 3
show 2 more results
-33.2 score @ 3wk
NCT00954122 · Phase 4 · registry result, not featured evidence
-26.8 score @ 8.14wk
NCT00779506 · Phase 4 · registry result, not featured evidence
PANSS Positive 2.36 score @ 24wk
absolute change · score
No placebo or comparator arm
NCT00640601 · Phase 3
show 1 more result
-7.4 score @ 8.14wk
NCT00779506 · Phase 4 · registry result, not featured evidence
PANSS Negative 3.67 score @ 24wk
absolute change · score
No placebo or comparator arm
NCT00640601 · Phase 3
show 1 more result
-6.2 score @ 8.14wk
NCT00779506 · Phase 4 · registry result, not featured evidence
GAS 5.54 score @ 24wk
absolute change · score
No placebo or comparator arm
NCT00640601 · Phase 3
CGI-S 0.51 score @ 24wk
absolute change · score
No placebo or comparator arm
NCT00640601 · Phase 3
show 2 more results
-1.2 score @ 3wk
NCT00954122 · Phase 4 · registry result, not featured evidence
-1.46 score @ 8.14wk
NCT00779506 · Phase 4 · registry result, not featured evidence
CGI-I 0.55 score @ 24wk
absolute change · score
No placebo or comparator arm
NCT00640601 · Phase 3
show 1 more result
2.4 score @ 3wk
NCT00954122 · Phase 4 · registry result, not featured evidence
SOFAS 6.45 score @ 24wk
absolute change · score
No placebo or comparator arm
NCT00640601 · Phase 3
CDSS 7.31 vs 5.53 Risperidone score @ 12wk
absolute change · score
NCT00640562 · Phase 3
HAM-D -29.83 vs -23.02 Risperidone score @ 12wk
absolute change · score
NCT00640562 · Phase 3
CGI-S -1.5 vs -1.04 Risperidone score @ 12wk
absolute change · score
NCT00640562 · Phase 3
show 1 more result
-1.4 vs -0.9 placebo score @ 6wk
NCT01810380 · Phase 3 · registry result, not featured evidence

+ 21 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Iloperidone (Fanapt)'s landscape · Quetiapine (Seroquel XR)'s landscape